Agios Pharmaceuticals, Inc.

NasdaqGS:AGIO Stock Report

Market Cap: US$2.0b

Agios Pharmaceuticals Future Growth

Future criteria checks 2/6

Agios Pharmaceuticals's earnings are forecast to decline at 29.7% per annum while its annual revenue is expected to grow at 48.3% per year. EPS is expected to decline by 32.9% per annum. Return on equity is forecast to be -21% in 3 years.

Key information

-29.7%

Earnings growth rate

-32.9%

EPS growth rate

Biotechs earnings growth29.6%
Revenue growth rate48.3%
Future return on equity-21.0%
Analyst coverage

Good

Last updated06 Feb 2025

Recent future growth updates

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Recent updates

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision

Jan 14

Agios Pharmaceuticals: A Long Overdue Follow Up

Dec 03

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Sep 26
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 27

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06
We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18
Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios adds more than 13% after Novo deal to acquire rival Forma

Sep 01

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Aug 04

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Jul 26

Agios Pharmaceuticals appoints new board chair, CEO

Jul 12

Agios: Approved Product, Upcoming Catalysts

May 10

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 10
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Earnings and Revenue Growth Forecasts

NasdaqGS:AGIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027444-114-36-2064
12/31/2026182-326-286-3157
12/31/202595-368-248-3219
12/31/202435673-302-3039
9/30/202433674-330-329N/A
6/30/202431-365-325-307N/A
3/31/202429-353-319-301N/A
12/31/202327-352-315-296N/A
9/30/202324-220-308-290N/A
6/30/202320-210-300-299N/A
3/31/202319-218-309-307N/A
12/31/202214-232-314-309N/A
9/30/202210-367-337-327N/A
6/30/20226-369-350-341N/A
3/31/20221-360-392-384N/A
12/31/2021N/A-357-413-407N/A
9/30/2021N/A-342-374-373N/A
6/30/2021N/A-337-363-356N/A
3/31/2021N/A-336-317-306N/A
12/31/2020N/A-329-305-291N/A
9/30/202035-347-355-335N/A
6/30/202061-374-370-352N/A
3/31/202088-402-387-373N/A
12/31/2019N/A-301-383-371N/A
9/30/2019112-401-358-351N/A
6/30/2019102-389-337-329N/A
3/31/2019116-348-316-309N/A
12/31/201894-346-311-304N/A
9/30/201874-343-312-305N/A
6/30/201870-325N/A-319N/A
3/31/201841-339N/A-310N/A
12/31/201743-315N/A-285N/A
9/30/201756-283N/A-262N/A
6/30/201753-269N/A-233N/A
3/31/201749-241N/A-17N/A
12/31/201670-198N/A39N/A
9/30/201653-183N/A59N/A
6/30/201650-160N/A83N/A
3/31/201656-136N/A-70N/A
12/31/201559-118N/A-77N/A
9/30/201568-104N/A-54N/A
6/30/201596-60N/A-53N/A
3/31/201591-46N/A-58N/A
12/31/201465-54N/A-59N/A
9/30/201457-39N/A-65N/A
6/30/201430-55N/A-57N/A
3/31/201428-47N/A-71N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGIO's earnings are forecast to decline over the next 3 years (-29.7% per year).

Earnings vs Market: AGIO's earnings are forecast to decline over the next 3 years (-29.7% per year).

High Growth Earnings: AGIO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: AGIO's revenue (48.3% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: AGIO's revenue (48.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AGIO is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 07:34
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 31 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research
Alec StranahanBofA Global Research